Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Explainer-What has happened to the damaged spacecraft at China's space station? - 2Instructions to Augment the Presentation of Your Kona SUV
- 3IDF struck Iran's largest petrochemical plant, second facility hit in two days, Katz confirms
- 4New heart disease calculator predicts 30-year risk for young adults
- 5Russia patents space station designed to generate artificial gravity
- Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
- Israel’s 'Stonehenge’ not alone with near 30 similar sites, satellite imagery reveals
- 5 Chiefs That Changed Our Opinion on Film
- The Golden Globes gift bag has nearly $1 million worth of swag for some winners and presenters. What's in it?
- Pat Finn, actor from 'The Middle,' dies at 60 after bladder cancer diagnosis
- Dominating the Remote Work Way of life: Individual Systems
- From ‘Project Hail Mary’ to Artemis II, spaceflight captures audiences when it centers on people because human space travel is hazardous
- Manual for Tracking down One of a kind Store Inns
- Winter virus season so far is not too bad, but doctors worry about suffering to come
